Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-20
2005-09-20
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S307000, C514S357000, C514S475000, C514S618000, C514S654000
Reexamination Certificate
active
06946441
ABSTRACT:
The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
REFERENCES:
patent: 6706686 (2004-03-01), Long et al.
patent: 2002/0061860 (2002-05-01), Li et al.
patent: 2002/0065282 (2002-05-01), Georges et al.
patent: 2002/0103192 (2002-08-01), Curtin et al.
patent: 1170008 (2002-01-01), None
patent: 1174438 (2002-01-01), None
patent: 2001/348340 (2001-12-01), None
patent: WO 00/23112 (2000-04-01), None
patent: WO 00/71703 (2000-11-01), None
patent: WO 01/14581 (2001-03-01), None
patent: WO 01/16106 (2001-03-01), None
patent: WO 01/17514 (2001-03-01), None
patent: WO 01/18045 (2001-03-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 01/42437 (2001-06-01), None
patent: WO 01/70675 (2001-09-01), None
patent: WO 02/26696 (2002-04-01), None
patent: WO 02/26703 (2002-04-01), None
patent: WO 02/30879 (2002-04-01), None
patent: WO 02/46129 (2002-06-01), None
patent: WO 02/46144 (2002-06-01), None
patent: WO 02/50285 (2002-06-01), None
patent: WO 02/051842 (2002-07-01), None
Cecil Textbook of Medicine, Goldman et al. (eds.), published 2000 by W.B. Saunders Company (PA), p. 217.
Bates et al., “A phase I study of FR901228(Depsipeptide), a histone deacetylase inhibitor,”American Society of Clinical Oncology Meeting 1999 Abstract, Abstract # 693, 1999, printed from www.medespace.com/cancero/doc/asco/1999
ouvdro/m_693.htm, May 7, 2001.
Butler et al., “Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase,”Clin. Cancer Res., 7:962-970, 2001.
Butler et al., “Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo,”Cancer Res., 60:5165-5170, 2000.
Coffey et al., “The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid,”Cancer Res., 61:3591-3594, 2001.
Furumai et al., “FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases,”Cancer Res., 62:4916-4921, 2002.
Gottlicher et al., “Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells,”EMBO J., 20:6969-6978, 2001.
Han et al., “Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1and gelsolin,”Cancer Research, 60:6068-6074, 2000.
Haq, “Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy,”J. Cell Biology, 151:117-129, 2000.
Hinnebusch et al., “The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation,”J. Nutr., 132:1012-1017, 2002.
Hoffmann et al., “Fluorescence-labeled octapeptides as substrates for histone deacetylase,”Bioconjugate Chem., 12:51-55, 2001.
Itazaki et al., “Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents,”J Antibiot(Tokyo), 43(12):1524-1532, 1990.
Jung et al., “Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation,”J. Med. Chem., 42:4669-4679, 1999.
Jung et al., “Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors,”Bioorganic&Medicinal Chemistry Letters, 7:1655-1658, 1997.
Jung et al., “Structure-activity data on inhibitors of histone deacetylase-in vivo enzyme inhibition of differentiation and inhibition of proliferation in leukemic cells,”Clin. Cancer Res., Suppl. 6: Abstract #336, 2000.
Jung, “Inhibitors of histone deacetylase as new anticancer agents,”Curr. Med. Chem., 8:1505-1511, 2001.
Katoh et al., “MEF2B is a component of a smooth muscle-specific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression,”J. Biol. Chem., 273:1511-1518, 1998.
Kim et al., “Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase,”Oncogene, 18:2461-2470, 1999.
Kitazono et al., “Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the NA=/I−symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells,”J. Clinical Endoc. Metabol., 86(7):3430-3435, 2001.
Komastsu et al., “Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity,”Cancer Res., 61:4459-4466, 2001.
Kramer et al., “Histone deacetylase as a therapeutic target,”Trends in Endoc. Metabolism, 12(7):294-300, 2001.
Lu et al., “Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases,”Proc. Natl Acad. Sci. USA, 97:4070-4075, 2000.
Mai et al., “Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrroly)-N-hydroxyy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation,”J. Med. Chem., 45:1778-1784, 2002.
Marks et al., “Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells,”J. Natl. Cancer Inst., 92(15):1210-1216, 2000.
Marks et al., “Inhibitors of histone deacetylase are potentially effective anticancer agents,”Clin. Cancer Res., 7:759-760, 2001.
Massa et al, “3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors,”J. Med. Chem., 44:2069-2072, 2001.
Nicol et al., “Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy,”The EMBO J., 20(11):2757-2767, 2001.
Patrone et al., “Up regulation of the RET gene expression by histone deacetylase inhibitor sodium butyrate: hints to the gene physiologic regulation and applications for mutations screening,”50thAnnual Meeting of the American Society of Human Genetics , Abstracts, Program No. 1047, 2000.
Salminen et al., “Neuronal apoptosis induced by histone deacetylase inhibitors,”Brain Res. Mol. Brain Res., 61:203-206, 1998.
Saunders et al., “Histone deacetylase inhibitors as potential anti-skin cancer agents,”Cancer Res., 59-399-409, 1999.
Skaletz-Rorowski et al., “The histone deacetylase inhibitors, trichostatin A and the new synthetic inhibitor M232, suprress the proliferation of corornary smooth muscle cells,”Eur. Heart J., Abstract Suppl., 21:272, Abstract #P1551, Aug./Sep. 2000.
Su et al., “A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library,”Cancer Res., 60:3137-3142, 2000.
Takahashi et al., “Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase,”Antibiotics, 49:453-457, 1996.
Taunton et al., “A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p,”Science, 272:408-411, 1996.
Ueda et al., “FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity,”J Antibiot(Tokyo), 47(3):301-310, 1994.
Vigushin et al., “Histone deacetylase inhibitors in cancer treatment,”Anticancer Drugs, 13:1-13, 2002.
Vigushin et al., “Trichostatin A is a histone deacetylase i
Bristow Michael
Long Carlin
McKinsey Timothy A.
Olson Eric N.
Fulbright & Jaworski
Henley III Raymond J.
Regents of the University of Colorado, A Body Corporation
The Board of Regents The University of Texas System
LandOfFree
Inhibition of histone deacetylase as a treatment for cardiac... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of histone deacetylase as a treatment for cardiac..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of histone deacetylase as a treatment for cardiac... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3367712